Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

Fig. 5

Tumor burden and ctDNA correlation. Scatterplot of BRAF/NRAS mutant copy number (y-axis) and total metabolic tumor volume (x-axis) (a). Scatterplot of BRAF/NRAS mutant copy number (y-axis) distribution in terms of number of metastatic sites (x-axis) (b). Box plots detailing the ctDNA median copy numbers for the three groups of patients: high tumor burden (H), intermediate tumor burden (I) and low tumor burden (L) at baseline evaluation (c). Characterization of BRAF/NRAS mutant copy number distribution for baseline in the three groups by descriptive statistics (median, range, IQR, mean, std. deviation)

Back to article page